Burning mouth syndrome responsive to pramipexol

J Headache Pain. 2008 Feb;9(1):43-5. doi: 10.1007/s10194-008-0003-4. Epub 2008 Jan 25.

Abstract

Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improvement with pramipexol, a nonergot dopamine agonist which has high selectivity for dopaminergic D2 receptors. We discuss potential pathophysiological implications of our findings.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Benzothiazoles / administration & dosage*
  • Burning Mouth Syndrome / drug therapy*
  • Burning Mouth Syndrome / metabolism
  • Burning Mouth Syndrome / physiopathology
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Corpus Striatum / physiopathology
  • Dopamine / metabolism
  • Dopamine Agonists / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Resistance / drug effects
  • Drug Resistance / physiology
  • Female
  • Humans
  • Mouth Mucosa / drug effects*
  • Mouth Mucosa / innervation
  • Mouth Mucosa / physiopathology
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology
  • Pramipexole
  • Prospective Studies
  • Receptors, Dopamine D2 / agonists*
  • Receptors, Dopamine D2 / metabolism
  • Restless Legs Syndrome / drug therapy
  • Restless Legs Syndrome / physiopathology
  • Substance Withdrawal Syndrome / physiopathology
  • Treatment Outcome

Substances

  • Benzothiazoles
  • Dopamine Agonists
  • Receptors, Dopamine D2
  • Pramipexole
  • Dopamine